Humikind Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
- Revenue Growth 46.94%
- Profit Growth -9.93%
- Ebitda 18.96%
- Net Worth 21.70%
- Total Assets 48.55%
About Humikind Pharmaceutical
Humikind Pharmaceutical Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 October 2017 (Seven years and four months 5 days old ). Its registered office is in Faridabad, Haryana, India.
The Corporate was formerly known as Humi Kind Pharmaceutical Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Etendra Srivastava and Shivendra Srivastava serve as directors at the Company.
Company Details
- Location
Faridabad, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299HR2017PTC071181
- Company No.
071181
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Oct 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Humikind Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Etendra Srivastava  | Whole-Time Director | 18-Oct-2017 | Current |
| Shivendra Srivastava | Director | 18-Oct-2017 | Current |
Financial Performance of Humikind Pharmaceutical.
Humikind Pharmaceutical Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 46.94% increase. The company also saw a slight decrease in profitability, with a 9.93% decrease in profit. The company's net worth Soared by an impressive increase of 21.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Humikind Pharmaceutical?
In 2020, Humikind Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jan 2020 | Others | ₹1.00 M | Open |
How Many Employees Work at Humikind Pharmaceutical?
Unlock and access historical data on people associated with Humikind Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Humikind Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Humikind Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.